# US 2022/0031646 A1 · Dietary Supplements and Composition for Treating Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031646 A1
- Document ID: US20220031646A1
- Status: Published application
- Kind: A1
- Application number: 17/502,665
- Filed: 2021-10-15
- Published: 2022-02-03
- Earliest claimed: 2013-07-01
- Assignees: Memorial Sloan Kettering Cancer Center; The Trustees of Princeton University
- Applicants: Memorial Sloan-Kettering Cancer Center; The Trustees of Princeton University
- Inventors: Joshua D. Rabinowitz; Craig B. Thompson; Jiangbin Ye; Jing Fan; Jurre Kamphorst
- Web page: https://patentgrep.com/patent/US20220031646A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A23L 33/175: Amino acids
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Methods and compositions for treating cancer and other disorders associated with undesired cellular proliferation are provided comprising administering to a subject in need thereof an amino acid mixture, wherein the amino acid mixture comprises glycine, optionally comprising at least a 2:1 molar ratio of glycine to serine.

## Claims

### Claim 1

A nutritional supplement comprising an amino acid mixture, wherein the amino acid mixture comprises at least a 2:1 molar ratio of glycine to serine.

### Claim 2 (depends on 1)

The nutritional supplement of claim 1, wherein the molar ratio of glycine to serine in the supplement is about 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1.

### Claim 3 (depends on 1)

The nutritional supplement of claim 1, wherein the supplement is substantially devoid of serine.

### Claim 4 (depends on 1)

The nutritional supplement of claim 1, wherein the amino acid mixture comprises amino acids in free form, in prodrug form, salts, or amino acid esters.

### Claim 5 (depends on 1)

The nutritional supplement of claim 1, further comprising recombinantly synthesized protein deficient in serine.

### Claim 6

A nutritional supplement that is high in serine and low in glycine, wherein high serine is at least 2, 3, 4, 5 or 6 times the average daily intake of serine based on average daily total protein consumption.

### Claim 7 (depends on 6)

The nutritional supplement of claim 6 wherein the molar ratio of serine to glycine is about 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1.

### Claim 8

A nutritional supplement that is high in glycine and low in serine, wherein high glycine is at least 2, 3, 4, 5 or 6 times the average daily intake of glycine based on average daily total protein consumption.

### Claim 9

A pharmaceutical composition comprising high glycine, optionally comprising low serine, and a pharmaceutically acceptable carrier, wherein high glycine is at least 2, 3, 4, 5 or 6 times the average daily intake of glycine based on average daily total protein consumption.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9 wherein the molar ratio of glycine to serine in the composition is about 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, or 100:1.

### Claim 11 (depends on 9)

The pharmaceutical composition of claim 9 that is substantially devoid of serine.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method of treating cancer comprising administering to a subject in need thereof a diet comprising the nutritional supplement of any one of claims 1-8 or a pharmaceutical composition of any one of claims 9-11.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A method of treating cancer comprising administering to a subject in need thereof one or more pharmacological inhibitors of cancer cell growth and instructing the subject to consume a diet comprising the nutritional supplement of any one of claims 1-8.

### Claim 14 (depends on 13)

The method of claim 13, wherein the subject is further instructed to consume a diet low in serine, methionine, choline, or a combination thereof.

### Claim 15 (depends on 13)

The method of claim 13, wherein the subject is additionally instructed to consume a supplement comprising homocysteine.

### Claim 16 (depends on 13)

The method of claim 13, wherein the pharmacological inhibitor is an inhibitor of folate metabolism.

### Claim 17 (depends on 16)

The method of claim 16, wherein the inhibitor of folate metabolism is methotrexate or pemetrexed.

### Claim 18 (depends on 13)

The method of claim 13, wherein the pharmacological inhibitor is an inhibitor of DNA methylation.

### Claim 19 (depends on 18)

The method of claim 18, wherein the inhibitor of DNA methylation is azacytidine.

### Claim 20

A method of treating cancer comprising administering to a subject in need thereof a nutritional supplement of pharmaceutical composition comprising at least a 2:1 molar ratio of glycine to serine

### Claim 21 (depends on 20)

The method of claim 20 wherein the treatment is administered over a time period of at least 2 weeks.

### Claim 22 (depends on 21)

The method of claim 21 wherein the treatment is administered over a time period of 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 25 weeks, 26 weeks, or until a therapeutic endpoint is observed.

### Claim 23

A method of treating cancer in a subject comprising administering a chemotherapeutic agent and a pharmaceutical composition or nutritional supplement comprising high glycine, wherein the subject is administered about 4-8 g, 6-10 g, or 4-12 g of glycine daily.

### Claim 24 (depends on 23)

The method of claim 23 wherein the glycine is administered 1, 2, 3 or 4 times daily to achieve the total daily dose of glycine.

### Claim 25 (depends on 23)

The method of claim 23 wherein the chemotherapeutic agent is an antifolate.

### Claim 26

A method of treating cancer in a subject comprising administering a chemotherapeutic agent and a pharmaceutical composition or nutritional supplement comprising high serine, wherein the subject is administered about 4-8 g, 6-10 g, or 4-12 g of serine daily.

### Claim 27 (depends on 26)

The method of claim 26 wherein the chemotherapeutic is an antifolate.
